

Reference Number: FOI202223/001
From: Private Individual
Date: 01 April 2022
Subject: Treatment of myelofibrosis

Q1 Does your trust treat myelofibrosis? If not, which other trust do you refer these patients to?

A1 Yes

Q2 a. Please provide the total number of patients treated in the last 6 months (or the latest 6 months data you have available) for myelofibrosis (ICD10 code D47.4).

b. How many of these patients were above age 65?

A2 a. Zero

b. No applicable, Alder Hey Children's NHS Foundation Trust does not treat patients above the age of 65

Q3 How many myelofibrosis patients were treated in the past 6 months with Ruxolitinib?

A3 Information not held – this drug is not used at Alder Hey Children's NHS Foundation Trust

Q4 a. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

b. Of these patients, how many were treated in the past 6 months (or the latest 6 months data you have available) with:

- I. Hydroxyurea
- II. Fedratinib
- III. Received No Treatment

A4 a. Zero

b. Information not held – these drugs are not used at Alder Hey Children's NHS Foundation Trust

Q5 Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.

A5 No - we do not have any trials running for myelofibrosis.